Aethlon Medical CEO Named to Biodefense Panel at the 2006 Homeland and Global Security Summit.

SAN DIEGO -- Aethlon Medical, Inc. (OTCBB:AEMD), a pioneer in developing therapeutic devices for infectious disease, announced today that its Chairman and CEO, James A. Joyce has been named to the Biodefense Priorities, Programs, and Funding Panel at the 2006 Homeland and Global Security Summit. The Summit is being held on April 11 at the Washington Convention Center in Washington, D.C. The other panel members are:

--Steven Perkins, Vice President, Business Development and Strategy, Northrop Grumman Corporation.

--Dr. Charles R. Gallaway, Director, Chemical-Biological Defense Directorate, Defense Threat Regulatory Agency (DTRA).

--Major General Bruce E. Davis, Commander, Joint Task Force Civil Support, US Northern Command.

Additional details on the 2006 Homeland and Global Security Summit can be accessed at www.globalsecurity.bz/conferences/current_conferences/hgss/2006/index. asp.

About Aethlon Medical

Aethlon Medical is developing the first medical device to treat infectious disease. The device, known as the Hemopurifier(TM), is a broad-spectrum treatment countermeasure against drug and vaccine resistant bioweapons, naturally evolving pandemic threats such as H5N1 Avian Flu, and chronic infectious disease targets including Hepatitis-C (HCV) and the Human Immunodeficiency Virus (HIV). Aethlon has also initiated research on a second generation Hemopurifier(TM) that targets the capture of growth factors inherent in the spread of Cancer. More information on Aethlon Medical and the Hemopurifier(TM) technology can be found at www.aethlonmedical.com.

Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.